Biocartis Group NV: Disclosure of a transparency notification

 

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 19 April 2017 (the 'Notification'), indicating that as a result of the acquisition of voting securities on 19 April 2017, Sycomore Asset Management now holds 5.15% of the voting rights in Biocartis. As a result, it has crossed the notification threshold of 5%.

  • Reason for the Notification: acquisition or disposal of voting securities or voting rights.
     
  • Notification by: a person that notifies alone.
     
  • Persons subject to the notification requirement: Sycomore Asset Management, 14 avenue Hoche, 75 008 Paris, France.
     
  • Transaction date: 19 April 2017.
     
  • Threshold that is crossed: 5%.
     
  • Denominator: 44,648,105.
     
  • Details of the Notification: Sycomore Asset Management holds 2,301,126 voting securities.
     
  • Additional information: Sycomore Asset Management holds the participation solely in the framework of its activities as management company of UCI and UCITS and discretionary mandates.

 

The Notification is available here on the website of the Company.

 

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

Note

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers eight oncology tests and two infectious disease tests. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?